The FDA has given its approval to Ely Lilly and Company's new Alzheimer's testing procedure called Amyvid. The test uses a radioactive ink that allows doctors to screen for a plaque in the brain that has been tied to Alzheimer's.
According to foxnews.com, when injected into the bloodstream the radioactive ink binds the to harmful plaque beta amyloid, which is then illuminated on a positron emission topography scan.
Lilly will sell the product through its Avid Radiopharmaceuticals Inc. brand and the brand's CEO Dr. Daniel Skovronsky says it will add a new tool for doctors to use in diagnosing the ailment:
"The approval of Amyvid offers physicians a tool that, in conjunction with other diagnostic evaluations, can provide information to help physicians evaluate their patients," he said in the company's statement from Friday.
by RTT Staff Writer
For comments and feedback: firstname.lastname@example.org